Editas news

You're looking for news about Editas Medicine!

Editas Medicine is a biotechnology company that focuses on developing gene editing therapies using CRISPR technology. Here are some recent news updates about the company:

Recent News:

  1. Editas Medicine announces positive results from Phase 1 trial of EDIT-101 for Leber Congenital Amaurosis: In February 2023, Editas Medicine announced positive results from a Phase 1 clinical trial of EDIT-101, a CRISPR-based gene therapy for Leber Congenital Amaurosis (LCA), a rare inherited retinal disease. The trial showed that the treatment was well-tolerated and resulted in significant improvements in visual acuity and retinal function.
  2. Editas Medicine receives FDA orphan drug designation for EDIT-101 for LCA: In January 2023, the US Food and Drug Administration (FDA) granted orphan drug designation to EDIT-101 for the treatment of LCA. This designation provides Editas Medicine with seven years of market exclusivity for the treatment if it is approved.
  3. Editas Medicine announces collaboration with Biogen to develop gene therapies for neurological disorders: In December 2022, Editas Medicine announced a collaboration with Biogen to develop gene therapies for neurological disorders using CRISPR technology. The collaboration aims to leverage Editas Medicine's gene editing capabilities with Biogen's expertise in developing treatments for neurological disorders.

Upcoming Events:

  1. Editas Medicine's R&D Day: The company is hosting an R&D Day on March 15, 2023, where it will provide updates on its pipeline of gene editing therapies, including EDIT-101 for LCA and other programs.
  2. American Academy of Ophthalmology (AAO) Annual Meeting: Editas Medicine will be presenting data on its gene editing therapies for retinal diseases at the AAO Annual Meeting, which takes place from October 14-17, 2023.

Recent Financials:

  1. Editas Medicine reports Q4 2022 financial results: In February 2023, Editas Medicine reported its financial results for the fourth quarter of 2022. The company reported a net loss of $44.6 million, or $0.44 per share, compared to a net loss of $34.4 million, or $0.34 per share, in the same period in 2021.

I hope this information is helpful!